glutathione peroxidase 4 rabbit pab  (Bioss)

Journal: Bioactive Materials

Article Title: Regulating SLC7A11/GSH/GPX4 axis by glucose dyshomeostasis to simultaneously promote disulfidptosis, cuproptosis and ferroptosis

doi: 10.1016/j.bioactmat.2025.09.003

Figure Lengend Snippet: Schematic illustration of CuAp@GOx NSs preparation and therapy process. Schematic illustration for the preparation of CuAp@GOx NSs and the mechanism of glucose dyshomeostasis-disrupted SLC7A11/GSH/GPX4 antioxidant axis for disulfidptosis, cuproptosis and ferroptosis in tumor therapy.

Article Snippet: Rabbit anti-FDX1 polyclonal antibody, rabbit anti-LIAS polyclonal antibody, rabbit anti-DLAT polyclonal antibody, rabbit anti-GPX4 polyclonal antibody and rabbit anti-GAPDH antibody were obtained from Proteintech Group Inc. (Wuhan, China).

Techniques:

Journal: Bioactive Materials

Article Title: Regulating SLC7A11/GSH/GPX4 axis by glucose dyshomeostasis to simultaneously promote disulfidptosis, cuproptosis and ferroptosis

doi: 10.1016/j.bioactmat.2025.09.003

Figure Lengend Snippet: Cytotoxicity of CuAp@GOx NSs. (a) The CLSM images of SKOV3 cells stained by Hoechst 33342 after incubation with Rhodamine B-labeled CuAp@GOx NSs for 0, 2 and 6 h. (b) The cell viability of SKOV3 cells after treatment with CuAp@GOx NSs of different concentrations. (c) The Cu contents in IOSE-80 cells and SKOV3 cells after treatment with CuAp@GOx NSs for 1 and 2 h. The WB data (d) and the analysis (e) of GLUT1 in SKOV3 cells after treatment with CuAp@GOx NSs (3 μg/mL). (f) The total glucose content of SKOV3 cells after treatment with CuAp@GOx NSs of different concentrations. The WB data (g) and the analysis (h) of PKM2 in SKOV3 cells after treatment with CuAp@GOx NSs (3 μg/mL). (i) The intracellular NADP + /NADPH content of SKOV3 cells after treatment with CuAp@GOx NSs (3 μg/mL) for 0, 12 and 24 h. The WB data (j) and the analysis (k) of SLC7A11 in IOSE-80 cells and SKOV3 cells. (l) The intracellular GSH content of SKOV3 cells after treatment with CuAp@GOx NSs of different concentrations. (m) The fluorescence intensity of Coppersensor-1 in of SKOV3 cells after treatment with CuAp NSs and CuAp@GOx NSs. The WB data (n) and the analysis (o) of GPX4 in SKOV3 cells after treatment with CuAp@GOx NSs (3 μg/mL). Data in Figure b, c, e, f, h, i, k, m and o are presented as mean ± SD (n = 3). Data in Figure l are presented as median ± interquartile range (n = 3). Data in Figure f, i, k, l, m and o are analyzed by t -test. P -value: ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.

Article Snippet: Rabbit anti-FDX1 polyclonal antibody, rabbit anti-LIAS polyclonal antibody, rabbit anti-DLAT polyclonal antibody, rabbit anti-GPX4 polyclonal antibody and rabbit anti-GAPDH antibody were obtained from Proteintech Group Inc. (Wuhan, China).

Techniques: Staining, Incubation, Labeling, Fluorescence

Journal: Bioactive Materials

Article Title: Antibody-functionalized iron-based nanoplatform for ferroptosis-augmented targeted therapy of HER2-positive breast cancer

doi: 10.1016/j.bioactmat.2025.06.034

Figure Lengend Snippet: In vitro anti-tumor mechanism of FEH. a) Intracellular H 2 O 2 levels in SK-BR-3 cells treated with different formulations by hydrogen peroxide assay kit ( n = 3). b-d) Flow cytometric analyses and CLSM images of DCFH-DA-stained SK-BR-3 cells exposed to different treatments ( n = 3). e) Intracellular MDA levels in SK-BR-3 cells treated with different formulations ( n = 3). f) Observation of appropriate red-green fluorescence intensity ratio of SK-BR-3 stained with JC-1 using CLSM ( n = 3). g) Observation of mitochondrial morphological changes in tumor cells after 24 h of different treatments using TEM ( n = 3). h) Results of Western blot analysis of GPX4 and SLC7A11 expression in SK-BR-3 cells after the treatment with different treatments. ∗∗ p < 0.01, ∗∗∗ p < 0.001 compared with the control group; ### p < 0.001 compared with the FEH group. Data are presented as mean ± SD.

Article Snippet: Actin polyclonal antibody was purchased from Saierwei Biotech Co., Ltd. (Wuhan, China), and GPX4 monoclonal antibody was purchased from Boster Biological Engineering Co., Ltd. (Wuhan, China).

Techniques: In Vitro, H2O2 Assay, Staining, Fluorescence, Western Blot, Expressing, Control

Journal: Bioactive Materials

Article Title: Antibody-functionalized iron-based nanoplatform for ferroptosis-augmented targeted therapy of HER2-positive breast cancer

doi: 10.1016/j.bioactmat.2025.06.034

Figure Lengend Snippet: Anti-tumor efficacy of FEH in vivo . a) Schematic diagram of the establishment and treatment of the BT474 tumor-bearing mice model. b) The imaging of tumor-bearing mice after different anti-tumor treatments. c) The body weight change within the 14-day observation period ( n = 6). d-e) Tumor volume changes. f) The tumor weight on day 14. g) Images of H&E, Ki67, TUNEL staining and GPX4, SLC7A11 protein immunofluorescence of tumor tissues after different treatments. h) GPX4 and SLC7A11 expression in tumor tissue after different treatments. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001 compared with the control group.

Article Snippet: Actin polyclonal antibody was purchased from Saierwei Biotech Co., Ltd. (Wuhan, China), and GPX4 monoclonal antibody was purchased from Boster Biological Engineering Co., Ltd. (Wuhan, China).

Techniques: In Vivo, Imaging, TUNEL Assay, Staining, Immunofluorescence, Expressing, Control